If you have been reading about BPC-157 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Freeze-dried solid, often hygroscopic |
| Solubility class | Freely soluble in water | Aqueous buffers used for stock solutions |
| Storage, dry powder | Minus 20 °C or colder | Recommended for long-term retention |
| Storage, solution | 2–8 °C or frozen | Avoid repeated freeze-thaw cycles |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity percentage plus mass confirmation |
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
Vital Brazil Mineiro da Campanha (April 28, 1865 – May 8, 1950), was a Brazilian physician, biomedical scientist and immunologist, known for the discovery of the polyvalent anti-ophidic serum used to treat bites of venomous snakes of the Crotalus, Bothrops and Elaps genera. He went on to be also the first to develop anti-scorpion and anti-spider serums. He was the founder of the Butantan Institute, a research center located in São Paulo, which was the first in the world dedicated exclusively to basic and applied toxicology, the science of venomous animals.
== Sources == Broodbank, Cyprian (2013). The Making of the Middle Sea: A History of the Mediterranean from the Beginning to the Emergence of the Classical World. London: Thames & Hudson. ISBN 978-0-500-29208-2. Brown, K.; Fa, D. A.; Finlayson, G.; Finlayson, C. (2011). "Small game and marine resource exploitation by Neanderthals: the evidence from Gibraltar". Trekking the shore: changing coastlines and the antiquity of coastal settlement. Interdisciplinary contributions to archaeology. Springer. ISBN 978-1-4419-8218-6. Finlayson, C. (2019). The smart Neanderthal: bird catching, cave art, and the cognitive revolution. Oxford University Press. ISBN 978-0-19-251812-5. French, Jennifer (2021). Palaeolithic Europe: A Demographic and Social Prehistory. Cambridge University Press. ISBN 978-1-108-49206-5. Papagianni, D.; Morse, M. A. (2013). "Still with us?". Neanderthals rediscovered: how modern science is rewriting their story. Thames and Hudson. ISBN 978-0-500-77311-6. Reich, D. (2018). "Encounters with Neanderthals". Who we are and how we got here: ancient DNA and the new science of the human past. Oxford University Press. ISBN 978-0-19-882125-0. Shipman, P. (2015). "How humans and their dogs drove Neanderthals to extinction". The invaders: how humans and their dogs drove Neanderthals to extinction. Harvard University Press. doi:10.2307/j.ctvjf9zbs. ISBN 978-0-674-42538-5. JSTOR j.ctvjf9zbs. Tattersall, I. (2015). "Neanderthals, DNA, and creativity". The strange case of the Rickety Cossack: and other cautionary tales from human evolution. St. Martin's Publishing Group.
==== Pollination ==== Fertilization of the ovule occurs through wind pollination, via motile sperm, as in cycads, ferns, mosses, and algae. The sperm are large (about 70–90 μm) and are similar to the sperm of cycads, which are slightly larger. Ginkgo sperm were first discovered by the Japanese botanist Sakugoro Hirase in 1896. The sperm have a complex multi-layered structure, which is a continuous belt of basal bodies that form the base of several thousand flagella which have a cilia-like motion. The flagella/cilia apparatus pulls the body of the sperm forwards. The sperm have only a tiny distance to travel to the archegonia, of which there are usually two or three. Two sperm are produced, one of which successfully fertilizes the ovule. Fertilization of ginkgo ovules, and development of the embryos, occurs just before or after they fall from the tree in early autumn .
Sources: en.wikipedia.org
== Medical uses == Arsenic trioxide has emerged as a therapeutic agent in cancer treatment, especially for acute promyelocytic leukemia (APL). It achieves high remission rates, including among patients with relapsed disease, and offering advantages over other treatments like bone marrow transplantation and all-trans retinoic acid (ATRA), particularly by reducing toxicity and improving patient outcomes. The combined regimen of arsenic trioxide with ATRA is now considered a standard of care for newly diagnosed and relapsed APL, showing substantial efficacy even in pediatric and elderly populations. Arsenic trioxide is intended for the induction of remission and consolidation in adult patients with acute promyelocytic leukemia who have the t(15;17) translocation and/or the fusion of PML and RARα genes. The drug should be used after treatment failure or relapse. Prior therapy should include retinoid and chemotherapy. The current standard of care for acute promyelocytic leukemia (APL) is risk-adapted therapy based on the patient’s white blood cell count at diagnosis. For patients with non-high-risk APL (typically defined as a white blood cell count ≤10,000/μL), the preferred treatment is a chemotherapy-free regimen that combines all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), which has demonstrated superior efficacy and a favorable safety profile compared to regimens that include chemotherapy.
Each neurotransmitter has very specific degradation pathways at regulatory points, which may be targeted by the body's regulatory system or medication. Cocaine blocks a dopamine transporter responsible for the reuptake of dopamine. Without the transporter, dopamine diffuses much more slowly from the synaptic cleft and continues to activate the dopamine receptors on the target cell.
Amat-Mamu was a nadītu, a priestess to the god Shamash. She was the daughter of Sin-ilum (also transcribed as Sîn-ilum or Sin-ili). Sin-ilum was the son of Sin-tajjār, who in turn was the son of Akšāja. Amat-Mamu had a cousin, an aunt, and a great aunt who were all nadītus as well. Nadītus were sometimes allowed to choose their own heirs, including potential heirs outside of their own families. Such an option was allowed to the nadītu Belessunu, daughter of Mannium, as part of the terms of her own adoption as the heir of her aunt Naramtum, and Belessunu adopted Amat-Mamu as her heir. Amat-Mamu inherited four fields totaling 46 acres: a five-acre field and a 20 acre field in the Pzur-Ilaba district, a nine-acre field in the Akbarum district, and a 12 acre field in the Pahuşu district. She also inherited two plots of land: one and one-third sar of partially developed land in the cloister and six sar of undeveloped land of Sippar-rabum. Amat-Mamu inherited three slaves from Belessunu: Ana-pani-Šamaš-nadi, Sin-mašmaš, and Sin-mašmaš's brother. Also inherited were a house, two copper pots, and two axes. Amat-Mamu was given the deeds, or "mother tablets", entitling her to Belessunu's property. Per the terms of the agreement, Amat-Mamu was required to pay Belessunu's debts and provide for her while she lived. The debt totaled two-thirds mina, six shekels of silver. To provide for Belessunu, Amat-Mamu was required to provide Belessunu with six gurs of grain, 12 minas of wool, 24 liters of oil, six feasts, 20 liters of flour, and two pieces of meat each year.
Sources: en.wikipedia.org
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.
Reverse-phase liquid chromatography is used to assess purity, and mass spectrometry confirms molecular mass. Together these two checks form the most widespread approach. Some laboratories add amino acid analysis for further verification.
Yes. The peptide is freely soluble in water and in aqueous buffers, so reconstitution does not require an organic solvent. Stock solutions are usually prepared in water or a mild buffer. Exact handling depends on the intended downstream application.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.